Ann Arbor area medical devices startup Accuri Cytometers raised another $6 million in venture capital, the company announced this morning after issuing a filing Friday with the U.S. Securities and Exchange Commission.
The financing will help Accuri tailor its cell analysis device for use in the in vitro clinical diagnostics market, officials said.
The new funding comes after Accuri raised $4 million in 2009 and $13 million in 2008 -- financing that helped the firm expand its manufacturing capacity for its cell analysis device and introduce a key accessory to its main product.Ann Arbor-based venture capital firm Arboretum Ventures, a previous investor in Accuri, participated in the company's latest funding round. The InvestMichigan! Program, a venture capital fund managed for the state by global investment firm Credit Suisse, also provided financing along with Baird Venture Partners, Fidelity Biosciences and Flagship Ventures.
Click here to read the entire article:
Latest from Today's Medical Developments
- GrindingHub Americas launches in 2027 in Cincinnati, Ohio
- Methods Machine Tools now offers the Nakamura-Tome NT-Flex
- Battelle awards $900,000 in STEM education grants to Ohio schools
- #55 Lunch + Learn Podcast with KINEXON
- Starrett and Gerstner offer limited edition, American made 1950s replica wooden machinist tool chests
- EMCO’s UNIVERSALTURN 50: The new benchmark in universal turning
- Archetype's Expertise for Equity accelerates early-stage innovation
- Stratasys expands its AM solutions with Tritone's cutting-edge technology
